表一抗体药物通用名命名规则
人源化程度 | 靶点 | ||
-o- | 鼠源Mouse | -b/ba/bac- | 细菌感染 |
-a- | 兔源Rat | -ci/c- | 心血管 |
-axo- | 鼠兔嵌合 | -fu/f- | 真菌感染 |
-e- | 仓鼠Hamster | -ki/k- | 白介素 |
-i- | 灵长目Primate | -le/les- | 炎性病变 |
-xi- | 嵌合 | -li/l- | 免疫调节 |
-xizu- | 嵌合-人源化 | -ne/n- | 神经系统 |
-zu- | 人源化 | -so/os/s- | 骨科 |
-u- | 全人源 | -tox/toxa- | 毒素Toxin |
-tu/t- | 肿瘤 | ||
-vi/v- | 病毒 |
表二 FDA批准抗体药物
癌症 | 炎症性疾病 | 其他 |
Alemtuzumab | Adalimumab | Abciximab:心肌缺血并发症 |
Atezolizumab | Alemtuzumab | Alirocumab:高血脂 |
Bevacizumab | Belimumab | Basiliximab:器官移植排斥 |
Blinatumomab | Certolizumab pegol | Canakinumab:CAPS |
Brentuximab | Golimumab | Denosumab:骨质疏松 |
Catumaxomab | Infliximab | Ecolizumab:PNH、aHUS |
Cetuximab | Ixekizumab | Evolocumb:高血脂 |
Daratumumab | Natalizumab | primary |
dyslipidemia | Secukinumab | Idarucizumab:逆转达比加群酯 |
Denosumab | Tocilizumab | Mepolizumab:哮喘 |
coagulant | Ustekinumab | Obiltoxaximab:炭疽热 |
Dinutuximab | Vedolizumab | Omalizumab:哮喘 |
Elotuzumab | Palivizumab:RSV感染 | |
Ibrutumomab | Ranibizumab:AMD | |
Ipilimumab | Raxibacumab:炭疽热 | |
Necitumumab | Reslizumab:哮喘 | |
Nivolumab | ||
Obinutuzumab | ||
Ofatumumab | ||
Panitumumab | ||
Pembrolizumab | ||
Pertuzumab | ||
Ramucirumab | ||
Rituximab | ||
Siltuximab | ||
Trastuzumab | ||
Trastuzumab-emtansine |
作者信息
Armstrong
小编公众号:Biopharm2016
小编团队:Armstrong、医药局外人、Fairy、Jone
小编所有文章均为原创,欢迎关注。